Reported adverse reactions to the mRNA-1273 vaccine (Spikevax, Moderna Inc) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) range from mild, local delayed cutaneous reactions to rarer, more serious reactions such as myocarditis. Here, we describe the presentation and successful treatment of delayed, localized necrotizing inflammatory myositis following a third dose of the mRNA-1273 SARS-CoV-2 vaccine. To our knowledge, this is the first report of biopsy-confirmed, delayed inflammatory myositis after administration of an mRNA-1273 SARS-CoV-2 vaccine booster.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578160 | PMC |
| http://dx.doi.org/10.1093/ofid/ofac499 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Detection of multiple myositis-specific antibodies: prevalence and clinical significance.
Lab Med
January 2025
Immunology Department, Habib Bourguiba University Hospital, University of Sfax, Sfax, Tunisia.
Background: The multipositivity of myositis-specific antibodies (MSAs) is uncommon. Our study aimed to assess the prevalence and the clinical relevance of multiple positive MSAs in routine practice.
Methods: A 10 year single-center retrospective study (2015-2024) was conducted reviewing all samples analyzed with the Dot Myositis EUROLINE (Euroimmun Germany).
Loss of TDP-43 Splicing Repression Occurs in Myonuclei of Inclusion Body Myositis Patients.
Ann Neurol
January 2025
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD.
Objective: Inclusion body myositis (IBM) is an idiopathic inflammatory myopathy with muscle pathology characterized by endomysial inflammation, rimmed vacuoles, and cytoplasmic mislocalization of transactive response DNA-binding protein 43 (TDP-43). We aimed to determine whether loss of TDP-43 splicing repression led to the production of "cryptic peptides" that could be detected in muscle biopsies as a useful biomarker for IBM.
Methods: We used an antisera against a neoepitope encoded by a TDP-43-dependent cryptic exon within hepatoma-derived growth factor-like protein 2 (HDGFL2) for immunohistochemical analysis on muscle biopsy samples of 122 patients with IBM, 181 disease controls, and 16 healthy controls without abnormal muscle pathology.
[Clinical characteristics and prognostic analysis of concurrent pneumonia in patients with idiopathic inflammatory myopathy].
Zhonghua Jie He He Hu Xi Za Zhi
January 2025
Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing100730, China.
To describe the clinical characteristics and to explore the prognostic factors of concurrent pneumonia (PJP) in patients with idiopathic inflammatory myopathy (IIM). We retrospectively enrolled consecutive IIM patients diagnosed with PJP at our center between January 2014 and December 2022. Fifty-eight IIM-PJP patients were enrolled in our study, with the age of 26-79 (56.
View Article and Find Full Text PDFThe Spectrum of Cutaneous and Systemic Manifestations Associated with Anti-PM/Scl: Insights from a Single Institution Case Series.
J Am Acad Dermatol
January 2025
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. Electronic address:
Magnetic resonance imaging in idiopathic inflammatory myopathies: deciphering the pattern of muscle involvement.
Neuromuscul Disord
November 2024
Department of Neurology, Neuroscience Faculty Center, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru 560029, India. Electronic address:
Idiopathic inflammatory myopathies (IIMs) constitute a group of immune-mediated disorders, affecting muscles. Our study aims to investigate the specific patterns of muscle involvement in subgroups of IIM. An ambispective and observational study was conducted.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!